Disclosures for "Lecanemab Maintenance Dosing in Early Alzheimer’s Disease: Support for Continued Dosing from Clinical, Pharmacology, and Modeling Data"
-
Larisa Reyderman has nothing to disclose.
-
Dr. Bhagunde has received personal compensation for serving as an employee of Eisai.
-
Dr. Penner has received personal compensation for serving as an employee of eisai. Dr. Penner has received personal compensation for serving as an employee of Zentalis. Dr. Penner has received personal compensation for serving as an employee of Biogen. Dr. Penner has stock in Biogen.
-
Dr. Charil has received personal compensation for serving as an employee of Eisai Inc..
-
Author has nothing to disclose
-
Dr. Hersch has received personal compensation for serving as an employee of Eisai Inc.. Dr. Hersch has stock in Voyager Therapeutics. The institution of an immediate family member of Dr. Hersch has received research support from NIH. Dr. Hersch has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc..
-
Dr. Kramer has received personal compensation for serving as an employee of Eisai Inc. Dr. Kramer has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Eisai Co., Ltd..